https://www.selleckchem.com/pr....oducts/BIRB-796-(Dor
comes for patients with cancer undergoing revascularisation for acute limb ischaemia. This is in line with current recommendations that patients with underlying malignancy should be considered strongly for revascularisation.Immune checkpoint blockade (IC therapies exhibit substantial clinical benefit in different cancers, but relatively low response rates in the majority of patients highlight the need to understand mutual relationships among immune features. Here, we reveal overall positive correlations among immune che
Like
Comment
Share
